Neuroimage 21 : 125135
Food and Drug Administration (FDA) accelerated approval for treating metabolic dysfunction-associated steatohepatitis (MASH), the first GLP-1 approved for this indication Metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), is a serious condition that occurs when fat accumulates in the liver, causing inflammation and damage, such as scarring (fibrosis), cirrhosis or liver failure
For the delivery of the active fragment of parathyroid hormone (PTH 134), conjugation at N-terminus showed better efficiency than C-terminal conjugation, but coadministration method was more efficient for the delivery of PTH 1-34 in the Caco-2 monolayer (Kristensen et al., 2015a)
This is a substance of abuse
Anes J, McCusker MP, Fanning S, Martins M
The impending patent cliff for semaglutide in India and other countries has become a keenly watched opportunity for various players, as it is expected to unlock a new therapy market for drugmakers, which is projected to unlock a $100 billion market opportunity by the end of this decade
